Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Withdrawn 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2Tumor-Agnostic 1Thoracic 1Sarcoma 1Other solid neoplasm 1Other neoplasm 1Lymphoid 1

Conditions

Melanoma 2Pain 1Osteosarcoma 1Lymphoma 1Endocrine Gland Neoplasms 1Depression 1Anxiety Disorders 1

Interventions

Nivolumab 114Ipilimumab 114pembrolizumab 108aldesleukin 76Cyclophosphamide 70fludarabine phosphate 51Interleukin-2 48Temozolomide 41Dacarbazine 36trametinib 33dabrafenib 30Bevacizumab 30sargramostim 29Radiotherapy 29incomplete Freund's adjuvant 27fludarabine 27Vemurafenib 25Radiosurgery 25Carboplatin 25Paclitaxel 23binimetinib 22Biopsy 22CTLA-4 Antigen 21Peripheral Blood Stem Cell Transplantation 20encorafenib 19cemiplimab 19atezolizumab 19Mycophenolic Acid 19HhAntag691 19Aminolevulinic Acid 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Psilocybin × Dermatologic × Clear all
NCT06416085 2026-03-05

Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer

University Health Network, Toronto

Phase 2 Active not recruiting
15 enrolled
DermatologicLymphoidSarcoma

Endocrine Gland Neoplasms, Lymphoma, Melanoma, Osteosarcoma

NCT00979693 2023-12-26

Psilocybin-Assisted Psychotherapy for Anxiety in People With Stage IV Melanoma

Multidisciplinary Association for Psychedelic Studies

Phase 2 Withdrawn
Dermatologic

Anxiety Disorders, Depression, Melanoma, Pain

Data powered by HemOnc (CC BY 4.0) Colophon âš¡